JP2002500181A5 - - Google Patents

Download PDF

Info

Publication number
JP2002500181A5
JP2002500181A5 JP2000527236A JP2000527236A JP2002500181A5 JP 2002500181 A5 JP2002500181 A5 JP 2002500181A5 JP 2000527236 A JP2000527236 A JP 2000527236A JP 2000527236 A JP2000527236 A JP 2000527236A JP 2002500181 A5 JP2002500181 A5 JP 2002500181A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
riluzole
per day
composition according
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000527236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002500181A (ja
Filing date
Publication date
Priority claimed from IL12288398A external-priority patent/IL122883A0/xx
Priority claimed from IL12710298A external-priority patent/IL127102A0/xx
Application filed filed Critical
Priority claimed from PCT/IL1999/000003 external-priority patent/WO1999034785A2/en
Publication of JP2002500181A publication Critical patent/JP2002500181A/ja
Publication of JP2002500181A5 publication Critical patent/JP2002500181A5/ja
Pending legal-status Critical Current

Links

JP2000527236A 1998-01-09 1999-01-05 ジスキネジーの処置 Pending JP2002500181A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL12288398A IL122883A0 (en) 1998-01-09 1998-01-09 Pharmaceutical compositions for the treatment of dyskinesias
IL122883 1998-01-09
IL12710298A IL127102A0 (en) 1998-11-17 1998-11-17 Pharmaceutical compositions for the treatment of dyskinesias
PCT/IL1999/000003 WO1999034785A2 (en) 1998-01-09 1999-01-05 Treatment of dyskinesias
IL127102 1999-11-17

Publications (2)

Publication Number Publication Date
JP2002500181A JP2002500181A (ja) 2002-01-08
JP2002500181A5 true JP2002500181A5 (https=) 2006-03-02

Family

ID=26323572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000527236A Pending JP2002500181A (ja) 1998-01-09 1999-01-05 ジスキネジーの処置

Country Status (10)

Country Link
EP (1) EP1043996A2 (https=)
JP (1) JP2002500181A (https=)
KR (1) KR20010033978A (https=)
CN (1) CN1290166A (https=)
AU (1) AU1780699A (https=)
BR (1) BR9906821A (https=)
CA (1) CA2317811A1 (https=)
NO (1) NO20003529L (https=)
PL (1) PL342098A1 (https=)
WO (1) WO1999034785A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2790670A1 (fr) * 1999-03-12 2000-09-15 Aventis Pharma Sa Association riluzole et antagoniste des recepteurs ampa
AU3295900A (en) * 1999-03-12 2000-10-04 Aventis Pharma S.A. Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist
US6297254B1 (en) 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
FR2809620B1 (fr) * 2000-06-05 2002-08-02 Aventis Pharma Sa Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie
EP1256340B1 (en) * 2001-05-08 2003-08-13 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.

Similar Documents

Publication Publication Date Title
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
YU37301A (sh) Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa
JO2555B1 (en) Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent
WO2001019337A3 (en) Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
AU2277101A (en) Stable extended release oral dosage composition
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
AU7375598A (en) Stable oral pharmaceutical dosage forms
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
AU2276801A (en) Extended release oral dosage composition
PL348734A1 (en) New sustained release oral formulations
AU7001001A (en) Modified forms of pharmacologically active agents and uses therefor
YU14502A (sh) Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
AU5680100A (en) Controlled release and taste masking oral pharmaceutical compositions
WO2001032183A3 (en) Pharmaceutical compositions comprising oxcarbazepine
AU1724301A (en) Hydrogel-driven layered drug dosage form
WO2000078294A3 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
HUP0200386A3 (en) Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity and pharmaceutical compositions containing them and their use
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
AU2003238221A1 (en) Ibuprofen suspension
CA2325739A1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
BR0112847A (pt) Uso de uma forma de dosagem sólida
JP2002522501A5 (https=)
JP2002500181A5 (https=)
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.